---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000005"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T13:54:28.055010+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand Q4 net income $18.2M ($1.03 diluted); reaffirms 2024 guidance

## Summary
- Q4 total revenue $28.1M (down from $50.4M in Q4 2022, which included $23.5M COVID Captisol sales); core adjusted EPS $1.05 vs $0.75.
- Full-year 2023 royalties $83.9M (+16% YoY); core adjusted net income $71.7M ($4.06/diluted) vs $41.9M ($2.44).
- 2024 guidance reaffirmed: total revenue $130-142M, adjusted EPS $4.25-4.75.
- FDA approved ZELSUVMI (berdazimer gel) for molluscum contagiosum; Merck's V116 vaccine granted priority review (PDUFA June 17, 2024).
- Travere's FILSPARI sNDA for IgAN planned Q1 2024; FSGS data insufficient; Aldeyra received CRL for reproxalap.

## SEC filing metadata
- accession: 0000886163-24-000005
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/0000886163-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/lgnd-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000005
- JSON: https://secwatch.observer/filing/0000886163-24-000005.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000005.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported financial results for the three and twelve months ended December 31, 2023.
  - Period: the three and twelve months ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/0000886163-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.